Impact of docetaxel plus ramucirumab therapy on interstitial lung disease in recurrent advanced non-small cell lung cancer patients
DOC/RAM therapy significantly increased the incidence of interstitial pneumonia in NSCLC patients with pre-existing ILD but did not significantly affect efficacy outcomes such as ORR, PFS, or OS.
Authors
- Toyoshi Yanagihara (ORCID: https://orcid.org/0000-0002-2212-0631)
- Akira Nakao (ORCID: https://orcid.org/0000-0001-8308-4227)
- Yuki Shundo (ORCID: https://orcid.org/0000-0003-3459-951X)
- Noriyuki Ebi (ORCID: https://orcid.org/0000-0003-3140-4748)
- Masaki Fujita (ORCID: https://orcid.org/0000-0003-3202-5264)
- Yuta Fujimoto
- Maiya Chen
- Yusuke Osaki (ORCID: https://orcid.org/0000-0001-6588-5442)
- Hiroyuki Inoue (ORCID: https://orcid.org/0000-0002-8071-8797)
- Takato Ikeda (ORCID: https://orcid.org/0000-0003-3300-6225)
- Naoki Hamada (ORCID: https://orcid.org/0000-0001-9769-7999)
- Rei Sanai
- Natsumi Kushima
Institutions
- Fukuoka University Hospital (JP)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2024-10-01
- DOI
- https://doi.org/10.21037/tlcr-24-460
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00